A Study to Test if Fremanezumab Reduces Headache in Participants With Posttraumatic Headache (PTH)

Summary

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of fremanezumab in adult participants aged 18 to 70 years, inclusive, for the prevention of PTH. The study will include a double-blind (DB) treatment period (12 weeks) and an open-label (OL) treatment period (12 weeks).

Timeline

Start

2017-12-18

Primary completion

2020-03-13

Completion

2020-06-03

Drugs

Indications